Autopsy report · NCT05151471

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

“Futility Analysis of parent study MT-1186-A02 was met.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 9 months before it stopped.
• 202 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Shionogi

Sponsor type

Industry

Conditions

ALS

Interventions

MT-1186; Placebo

Participants

202

Sites

37

Countries

Canada, Germany, Japan, South Korea, Switzerland, United States

Trials that died the same way

• Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults
  “This study was terminated early due to futility.” (61% match in meaning)
• Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
  “Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301” (60% match in meaning)
• Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
  “Assessment for futility” (60% match in meaning)
• Tissue Adhesive vs. Sterile Strips After Cesarean Delivery
  “Based on results of an interim analysis, the study was halted for futility” (58% match in meaning)
• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
  “The result of a pre-planned interim futility analysis” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.